Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy

This pilot study (NCT03958097; https://www.clinicaltrials.gov/ct2/show/NCT03958097) was aimed to evaluate the efficacy and safety of PD-1 antibody combined autologous NK cells in the treatment of patients with stage IIIB/IIIC or IV non-small-cell lung cancer (NSCLC) who failed the first-line platinu...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Lin, Chen, Naifei, Chen, Xiao, Niu, Chao, Liu, Ziling, Ma, Kewei, Wang, Nanya, Yang, Lei, Zhao, Yuguang, Song, Wei, Lu, Jin, Chen, Chen, Cong, Xiaofeng, Wang, Xu, Xu, Yinghui, Cui, Guozhen, Liu, Zengguang, Chen, Rongrong, Li, Wei, Cui, Jiuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773193/
https://www.ncbi.nlm.nih.gov/pubmed/36569881
http://dx.doi.org/10.3389/fimmu.2022.1074906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773193/
https://www.ncbi.nlm.nih.gov/pubmed/36569881
http://dx.doi.org/10.3389/fimmu.2022.1074906

Ejemplares similares